EMA Issues Negative Opinion on AMX003 to Treat Adults with Amyotrophic Lateral Sclerosis (ALS)
source: pixabay.com

EMA Issues Negative Opinion on AMX003 to Treat Adults with Amyotrophic Lateral Sclerosis (ALS)

The long-awaited decision by the European committee CHMP was announced recently by Amylyx Pharmaceutical (the Company) based in Cambridge, Massachusetts just as anticipated. The EMA issued its negative opinion of…

Continue Reading EMA Issues Negative Opinion on AMX003 to Treat Adults with Amyotrophic Lateral Sclerosis (ALS)